港股異動 | 東陽光藥漲逾5% 發盈喜 獲機構看好
格隆匯2月27日丨東陽光藥(1558.HK)現報46.6港元,漲5.67%,暫成交2732萬港元,最新總市值209億港元。東陽光藥曾發盈喜公告指,預期集團2019年度的公司權益股東應占溢利將較2018年度錄得不低於120%的增長。預期增長主要是由於公司核心產品可威的銷售收入持續增長;公司產品於全國醫療機構滲透率不斷提升;及公司持續加強在專業學術界推廣產品。華泰證券指其2019年可威銷售超預期,1Q20有望維持強勁態勢,重申“買入”評級,目標價上調至56.8港元。中金亦維持跑贏行業評級和目標價59港元不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.